Novel, Fractionated Dosing Formulations for
Optimizing Titration of
Carbidopa/Levodopa
A Practical Roadmap for Improving Patient Satisfaction, Motor Symptoms,
Clinical Outcomes, and ON/OFF Time in Persons with PD
A Practical Roadmap for Improving Patient Satisfaction, Motor Symptoms,
Clinical Outcomes, and ON/OFF Time in Persons with PD
Featured Authorities on Parkinson’s Disease
Click on Speaker to View Their iQ&A Sessions
Associate Professor, Department of Neurology
Georgetown University Medical Center
Vice Chair of Finance
Director, Residency Program
Director, Botulinum Toxin Clinic
Associate Professor of Neurology
Medstar Georgetown University Hospital
Washington, D.C.
Professor and Director
Movement & Memory Disorder Programs
Department of Neurology
Medical College of Georgia
Augusta University
Augusta, Georgia
Center for Neurological Restoration
Professor of Medicine (Neurology)
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Neurological Institute, Cleveland Clinic
Cleveland, Ohio
Latest Videos |view all videos
Video
"Off time” may vary in severity at different times during the day due to physical activity and other factors, does this support the need to have different dosing options available in the manner provided by a scored, fractionated formulation of CD/LD?
Video
Can you please provide us with a brief summary of what you plan to cover in today’s CME program focusing on new advances in CD/LD-based treatment of PD, including the scored, fractionable dosing formulation of CD/LD?
Video
Dr. Morgan, we’re pleased to have you presenting on this program on new advances and formulations of CD/LD with a special focus on “off time.” Can you provide us with a summary of topics you will cover on today’s CME program?
Video
Once you commit to carbidopa/levodopa therapy, what is the typical starting dose, how long does it take for symptoms to ameliorate, and what should you expect in terms of long-term stability and/or deterioration (adverse fluctuations of ...
Video
If you embark on a therapeutic transition from standard CD/LD to the scored, fractionable dosing formulation of CD/LD, exactly how do you advise or counsel the patient on a titration plan?
Video
Once a patient is confirmed to have Parkinson’s Disease, what are the evidence- and guideline-based approaches to initiating pharmacotherapy and, sequencing therapy in cases that are refractory to initial therapy or that do not respond optimally?
Video
What formulations for CD/LD are approved and available for PD, and for once a person with PD begins to experience significant “off time” on CD/LD. What is your approach to minimizing deterioration in clinical symptoms?
Video
What is the role of fluctuating physical activity levels—hospital vs. rehab vs. home-based care—on the dose and dosing formulation of CD/LD and how does the CD/LD fractionable dosing formulation fit into the CD/LD titration equation?
Video
What minimal diagnostic criteria or clinical symptom severity do you feel is required to be actionable for pharmacologic treatment in a person presenting with a sign-symptom complex suggestive of PD?
